Who
David C. Sachs
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, ImmunityBio.
In numbers
- Trades disclosed
- 45
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 9 Sep 2021
- Last trade
- 22 Feb 2026
- Last filed
- 24 Feb 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 22 Feb 2026filed 24 Feb 2026 | IBRX ImmunityBioBiotechnology | SEC FORM 4 Code M | —40,650 at $0.00 | filing |
| 22 Feb 2026filed 24 Feb 2026 | IBRX ImmunityBioBiotechnology | SEC FORM 4 Code F | $180K20,682 at $8.70 | filing |
| 22 Feb 2026filed 24 Feb 2026 | IBRX ImmunityBiooption or derivative · Biotechnology | SEC FORM 4 Code M | —40,650 at $0.00 | filing |
| 22 Feb 2026filed 24 Feb 2026 | IBRX ImmunityBiooption or derivative · Biotechnology | SEC FORM 4 Code M | —40,650 at $0.00 | filing |
| 22 Feb 2026filed 24 Feb 2026 | IBRX ImmunityBioBiotechnology | SEC FORM 4 Code M | —40,650 at $0.00 | filing |
| 22 Feb 2026filed 24 Feb 2026 | IBRX ImmunityBioBiotechnology | SEC FORM 4 Code F | $180K20,682 at $8.70 | filing |
| 10 Feb 2026filed 12 Feb 2026 | IBRX ImmunityBioBiotechnology | SEC FORM 4 Code M | —82,236 at $0.00 | filing |
| 10 Feb 2026filed 12 Feb 2026 | IBRX ImmunityBioBiotechnology | SEC FORM 4 Code F | $296K42,643 at $6.93 | filing |
| 10 Feb 2026filed 12 Feb 2026 | IBRX ImmunityBiooption or derivative · Biotechnology | SEC FORM 4 Code M | —82,236 at $0.00 | filing |
| 10 Feb 2026filed 12 Feb 2026 | IBRX ImmunityBiooption or derivative · Biotechnology | SEC FORM 4 Code M | —82,236 at $0.00 | filing |
| 10 Feb 2026filed 12 Feb 2026 | IBRX ImmunityBioBiotechnology | SEC FORM 4 Code M | —82,236 at $0.00 | filing |
| 10 Feb 2026filed 12 Feb 2026 | IBRX ImmunityBioBiotechnology | SEC FORM 4 Code F | $296K42,643 at $6.93 | filing |
| 31 Dec 2025filed 5 Jan 2026 | IBRX ImmunityBioBiotechnology | SEC FORM 4 Code M | —30,397 at $0.00 | filing |
| 31 Dec 2025filed 5 Jan 2026 | IBRX ImmunityBioBiotechnology | SEC FORM 4 Code F | $31K15,435 at $1.98 | filing |
| 31 Dec 2025filed 5 Jan 2026 | IBRX ImmunityBiooption or derivative · Biotechnology | SEC FORM 4 Code M | —30,397 at $0.00 | filing |
| 31 Dec 2025filed 5 Jan 2026 | IBRX ImmunityBiooption or derivative · Biotechnology | SEC FORM 4 Code M | —30,397 at $0.00 | filing |
| 31 Dec 2025filed 5 Jan 2026 | IBRX ImmunityBioBiotechnology | SEC FORM 4 Code M | —30,397 at $0.00 | filing |
| 31 Dec 2025filed 5 Jan 2026 | IBRX ImmunityBioBiotechnology | SEC FORM 4 Code F | $31K15,435 at $1.98 | filing |
| 22 Feb 2025filed 25 Feb 2025 | IBRX ImmunityBiooption or derivative · Biotechnology | SEC FORM 4 Code M | —40,650 at $0.00 | filing |
| 22 Feb 2025filed 25 Feb 2025 | IBRX ImmunityBioBiotechnology | SEC FORM 4 Code M | —40,650 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.